debt_leverage_profile
Early-stage biotech; likely minimal debt, equity-financed; 20% rate rise immaterial but extends cash runway pressure
Inferred
Agent_Inference
interest_rate_sensitivity
Low direct debt sensitivity; higher rates increase opportunity cost of capital and compress biotech valuations by ~20-30%
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Active pharmaceutical ingredient sourcing from China/India; specialized reagent suppliers concentrated in EU create dual chokepoints
Inferred
Agent_Inference
international_expansion_readiness
Pre-revenue or early-revenue stage; negligible international revenue exposure; currency devaluation risk effectively null
Inferred
Agent_Inference
geographic_footprint
Primarily US-based operations; minimal international revenue footprint; currency devaluation exposure near zero currently
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency likely on single CRO partners and specialized API manufacturers; substitution timeline 6-18 months minimum
Inferred
Agent_Inference
business_model_type_primary
Drug development/licensing; cloud termination would disrupt R&D data systems but not core therapeutic asset value
Inferred
Agent_Inference
business_model_type_secondary
Secondary reliance on SaaS platforms for clinical data management; 30-day termination would delay trials, not destroy IP
Inferred
Agent_Inference
switching_cost_profile
Moderate API/platform coupling risk in clinical data systems; core IP (patents, compounds) is cloud-agnostic
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is drug licensing/milestone payments; low Howey risk as returns tied to therapeutic outcomes not investor pooling
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Clinical trial patient data subject to HIPAA primarily; GDPR exposure if EU trials conducted; compliance infrastructure likely nascent
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; early-stage single-asset or small-pipeline biotech lacks market dominance to trigger regulatory scrutiny
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional/milestone-based licensing revenue; recurring revenue near 0% at current stage
Inferred
Agent_Inference
monetization_vector
Milestone payments, royalties, and potential asset licensing/partnerships; no subscription component currently
Inferred
Agent_Inference
pricing_architecture
Drug pricing subject to payer negotiation and formulary access; pricing power dependent on clinical differentiation and orphan status
Inferred
Agent_Inference
pricing_power_rating
Moderate-to-high if approved in orphan/specialty indication; low if competing in crowded therapeutic class without clear superiority
Inferred
Agent_Inference
target_gross_margin_bracket
Post-commercialization biotech gross margins typically 70-85%; pre-revenue stage renders current gross margin negative
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage issue; IP protected by patents; unauthorized use of therapeutic compounds is a regulatory/legal matter
Inferred
Agent_Inference
headcount_cost_structure
R&D-intensive; growth largely sublinear via CRO outsourcing; doubling pipeline does not require doubling internal headcount
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost driven by clinical trial spend (CRO fees, patient enrollment); largely variable and outsourced, not headcount-linear
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC becomes payer/health system negotiation cost; patient access programs and formulary placement dominate economics
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; therapeutic efficacy and IP exclusivity drive value, not user-base compounding
Inferred
Agent_Inference
asset_efficiency_ratio
-38.9% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate; specialty/rare disease therapeutics relatively recession-resistant; funding environment for biotech highly cyclical
Inferred
Agent_Inference
customer_segment_primary
Patients and prescribing physicians in target therapeutic area; payers/PBMs as ultimate reimbursement gatekeepers
Inferred
Agent_Inference
customer_segment_secondary
Pharmaceutical licensing partners and potential acquirers representing concentrated deal-flow risk if single partnership dominates
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.6% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001919246
High
SEC-EDGAR
ticker
PTHS
High
SEC-EDGAR